CCR5/delta(ccr5) heterozygosity: a selective pressure for the syncytium-inducing human immunodeficiency virus type 1 phenotype. NIAID AIDS Clinical Trials Group Protocol 241 Virology Team.
Mechanisms underlying the delay in dominance of syncytium-inducing (SI) phenotype HIV-1 (human immunodeficiency virus type 1) in vivo are unknown. Both random mutational events and selective pressures operative only late in the disease process have been suggested to underlie the shift from CCR5 to alternative coreceptor usage. Among the moderately advanced patients who entered AIDS Clinical Trials Group protocol 241, SI viral phenotype was more common among CCRS/delta(ccr5) heterozygotes (7/7, 100%) than among CCR5/CCR5 homozygotes (29/88, 33%; P < .001, Fisher's exact test). Other characteristics did not differ at study entry by CCR5 genotype, including median CD4 cell counts, plasma RNA levels, and infectious HIV-1 titers in circulating cells. These data indicate that CCR5/delta(ccr5) heterozygosity, which decreases cell-surface levels of CCR5 available to serve as an HIV-1 entry coreceptor, is a selective pressure for evolution of T cell line-tropic viruses that use an alternative coreceptor.
D'Aquila
R T
RT
Massachusetts General Hospital, Harvard Medical School, Boston, USA. daquila@helix.mgh.harvard.edu
Sutton
L
L
Savara
A
A
Hughes
M D
MD
Johnson
V A
VA
D000328:Adult; D005260:Female; D005838:Genotype; D015726:Giant Cells / Q000821:virology; D015658:HIV Infections / Q000235:genetics / Q000378:metabolism / Q000821:virology*; D015497:HIV-1 / Q000235:genetics* / Q000472:pathogenicity; D006579:Heterozygote; D006801:Humans; D008297:Male; D010641:Phenotype; D019713:Receptors, CCR5 / Q000235:genetics* / Q000378:metabolism; D012641:Selection, Genetic
D019713:Receptors, CCR5